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Introduction {#sec005}
============

Anterior uveitis, the most common type of intraocular inflammation, is the most commonly associated with the elevation of intraocular pressure (IOP). The etiology of anterior uveitis includes infectious, non-infectious, and secondary origin to masquerade syndrome. The most common form of anterior uveitis is HLA-B27 associated uveitis, in which IOP is often reduced. Contrary to the HLA-B27 associated uveitis, anterior uveitis secondary to virus infection is characterized by the elevation of IOP at the time of inflammation. The three main herpes viruses, herpes simplex virus (HSV)-1, varicella zoster virus, and CMV have been focused as a cause of anterior uveitis \[[@pone.0218471.ref001]\].

Among the herpes viruses, CMV has been increasingly recognized as a cause of acute recurrent or chronic anterior uveitis associated with ocular hypertension or corneal endotheliitis in immunocompetent patients \[[@pone.0218471.ref002], [@pone.0218471.ref003]\]. High CMV viral loads have been correlated with number of recurrences and corneal endothelial damage \[[@pone.0218471.ref004], [@pone.0218471.ref005]\]. Longer duration of uveitis and frequent relapses lead to glaucomatous damage in 24--26% of cases \[[@pone.0218471.ref006]\]. Among the forms of viral anterior uveitis, CMV anterior uveitis is known to accompany a higher number of eyes requiring glaucoma filtering surgery and severe corneal endothelial cell loss compared with CMV-negative cases \[[@pone.0218471.ref007]\]. The potentially vision-threatening complications of the CMV anterior uveitis may attribute to the intrinsic characteristics of the pathogen. The antivirals routinely used for HSV and VZV do not treat CMV anterior uveitis. In addition, the systemic anti-CMV agent carries systemic side effects requiring routine lab monitoring, which hinders long term systemic anti-viral prophylaxis in CMV anterior uveitis.

In many CMV uveitis cases, there is generally a clinical response to topical steroid and anti-CMV agents, only to recur with the cessation of treatment \[[@pone.0218471.ref003], [@pone.0218471.ref008]\]. The development of novel disease-modifying drugs based on the pathogenic mechanism is therefore necessary for more effective treatment of CMV anterior uveitis.

CMV infection is associated with many fibrotic diseases such as congenital hepatic fibrosis, idiopathic pulmonary fibrosis, enhanced chronic renal allograft rejection, and idiopathic pulmonary fibrosis \[[@pone.0218471.ref009]--[@pone.0218471.ref011]\]. Transforming growth factor (TGF)-β1, a fibrogenic cytokine, is highly expressed in CMV-infected renal allografts \[[@pone.0218471.ref012]\]. CMV infection induces TGF-β1 secretion in renal epithelial cells, astrocytes, osteosarcoma cells, and fibroblasts *in vitro* \[[@pone.0218471.ref013]--[@pone.0218471.ref015]\]. In a previous study, we found that CMV successfully replicated and enhanced TGF-β1 production in human trabecular meshwork (TM) cells \[[@pone.0218471.ref016]\], the key cell type regulating IOP \[[@pone.0218471.ref017]\]. In addition, CMV infection is thought to aggravate fibrosis through the activation of TGF-β1 \[[@pone.0218471.ref011]\].

TGF-β is increased in the aqueous humor in glaucoma patients and is one of the major molecular signatures of this disorder \[[@pone.0218471.ref018]\]. Increased TGF-β induces pro-fibrotic signaling, ultimately resulting in accelerated accumulation of extracellular matrix (ECM) and stiffening of the TM cells, which leads to an increase in outflow resistance \[[@pone.0218471.ref017]\]. In the modulation of the ECM outflow pathway, the ocular renin-angiotensin system (RAS) has been thought to be a potential therapeutic target \[[@pone.0218471.ref019]--[@pone.0218471.ref021]\]. RAS systemically regulates blood pressure homeostasis, systemic fluid volume, and electrolyte balance. In addition to these obligatory roles, angiotensin II regulates fibrosis, inflammation, proliferation, and vasoconstriction. RAS inhibitors have been successfully used in the treatment of cardiovascular diseases involving extensive ECM remodeling in the myocardium and in fibrotic conditions affecting the kidneys \[[@pone.0218471.ref022], [@pone.0218471.ref023]\]. As a paracrine system, RAS components and their downstream targets are known to exist in human TM cells \[[@pone.0218471.ref019]\]. Based on the pro-fibrotic changes induced by CMV infection, we hypothesized that the inhibition of RAS in human TM cells may have therapeutic benefit in patients with CMV-induced hypertensive anterior uveitis. Considering the role of TM cells in the regulation of IOP, a model of CMV infection in human TM cells could be a useful tool to test the pathogenic mechanism of CMV hypertensive anterior uveitis. In the present study, we investigated the effects of losartan, a selective angiotensin II type 1 receptor (AT1R) inhibitor in association with CMV-induced changes in TM cells, and compared its effects with those of current treatment strategies, including steroid and anti-viral agent.

Methods {#sec006}
=======

Materials {#sec007}
---------

The following reagents were obtained from the respective commercial vendors. Recombinant human TGF-β1 from R&D Systems (Minneapolis, MN, USA), losartan from Selleck Chemicals (Houston, TX, USA), dexamethasone from Sigma-Aldrich (St. Louis, MO, USA), ganciclovir from Selleck Chemicals, normal horse serum (RTU Vectastain Universal Elite ABC Kit) from Vector Laboratories (Burlingame, CA, USA), murine monoclonal anti-CMV IE antibody (anti-CMV Immediate Early Antigen Antibody, \#LS-C103255) from LSBio (Seattle, WA, USA), a goat anti-mouse antibody (VectaFluor R.T.U. DyLight 488 anti-mouse) from Vector Laboratories, rhodamine phalloidin and Vecta-Stain mounting media (VECTASHIELD) from Invitrogen (Carlsbad, CA, USA), a TGF-β1 enzyme-linked immunosorbent assay (ELISA) kit (Total TGF-β1 ELISA Kit with precoated plates) from BioLegend (San Diego, CA, USA), and a MTS assay kit (CellTiter 96^®^ AQueous One Solution Cell Proliferation Assay) from Promega (Medison, WI, USA).

Cells {#sec008}
-----

Human TM cells were derived from two separate donors aged 39 years (male) and 16 years (female) without any known ocular diseases. Informed consent for tissue donation was obtained from the patients or their relatives (from a parent in case of 16 years old donor), and the study protocols were approved by the Institutional Review Board at the Catholic University of Korea in accordance with the Declaration of Helsinki for experiments involving human tissues and samples. The TM tissues were dissected and cultured as previously described \[[@pone.0218471.ref024]\]. The maintenance growth medium contained low glucose Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 15% fetal bovine serum (Invitrogen-Gibco, Grand Island, NY, USA), 1% penicillin-streptomycin, and fibroblast growth factor-2 (1 ng/mL). For repeated experiments, primary TM cells obtained from ScienCell Research Labs (Carlsbad, CA, USA) were used and cultured to 100% confluence in Trabecular Meshwork Cell Medium (ScienCell Research Labs) \[[@pone.0218471.ref025]\]. The TM cells in passage 4--6 were seeded into 6 well plates until the cells reached confluency.

Viruses {#sec009}
-------

Human foreskin fibroblasts (HFF) were used to propagate viral stocks. For purification, the cells were treated by freezing and thawing once, then centrifuged at 2,000 rpm for 20 min. Supernatant fluids were used as virus inoculum. Cell-free CMV was collected by filtration of the infected cell medium or extracted through a 0.45 μm filter, and loaded on a 10--55% sucrose gradient and centrifuged at 20,000 rpm for 1 h. The CMV pellet was washed and suspended in 2 ml of DMEM / 2% fetal bovine serum and was stored in aliquots at -80°C until use. Virus stocks were titrated by using a 50% tissue culture infectious dose (TCID~50~) assay on HFFs, using the method of Reed and Muench. When TM cells reached confluence, they were incubated with the virus stock preparation for a 2-h adsorption period at 37°C in 5% CO~2~ with a multiplicity of infection (MOI) of 1 and 0.1. After removal of the viral inoculum, the infected cells were washed once with 1× phosphate-buffered saline. All cell culture experiments were performed after serum starvation.

Viral DNA replication assays {#sec010}
----------------------------

TM cells seeded onto 6 well plates (4 x 10^5^ cells/well), and infected with CMV AD169 at MOI of 1 were treated with dexamethasone at 100 nM or ganciclovir at 10, 100 μM, or losartan at 1, 10 μM for 1, 3, 5 and 7 days, respectively. Human CMV capsids were pelleted from culture supernatants at 1, 3, 5, and 7 days post infection (dpi) and then resuspended and treated with DNase I. Capsids were disrupted using a Qiagen column (QIAmp DNA Mini Kit; Qiagen, Hilden, Germany), and DNA was quantitated by real-time quantitative PCR using nucleotide primers proven specific for the *AD169 UL26* gene \[[@pone.0218471.ref026]\]. Real-time PCR with β-actin primers was also performed to serve as an internal control for input DNA.

Cell viability assay {#sec011}
--------------------

The effects of dexamethasone, losartan, and ganciclovir on viability in cultured TM cells were evaluated using MTS assays. Cells were seeded at their optimal cell density (1×10^4^ cells/well) into a 96-well microtiter plate and were incubated overnight to allow cell attachment. Cells were treated with various concentrations of dexamethasone or losartan, or ganciclovir at 37°C under 5% CO~2~ for 1, 3, 5, and 7 days, respectively. At the end of each incubation period, the cell viability was determined according to the manufacturer\'s instructions.

Elisa for TGF-β1 {#sec012}
----------------

TM cells were grown in 6 wells plates, either untreated or infected with CMV AD169 at a MOI of 1 and/or incubated with dexamethasone at 100 nM or ganciclovir at 10, 100 μM, or losartan at 1, 10 μM for 1, 3, 5 and 7 days, respectively. The level of secreted TGF-β1 was measured by determining its concentration in conditioned medium using a commercially available sandwich ELISA kit at 1, 3, 5, and 7 dpi. Conditioned medium was harvested and cleared by centrifugation, then stored at −70°C. Conditioned medium was acid-activated and directly assayed using an ELISA plate reader at 450 nm according to the manufacturer's instructions. Protein concentrations were calculated from a standard curve with two-fold serial dilutions with the highest standard of 500 pg/mL.

Real-time PCR {#sec013}
-------------

TM cells were untreated, or infected with CMV AD169 at MOI of 1 and/or stimulated with recombinant active TGF-β1 at 15 ng/ml (0.6 nM) and/or treated with losartan (0.1 uM, 1 μM, 10 uM) for 48 hours \[[@pone.0218471.ref013]\]. Cells were washed, lysed and total RNA extracted using an RNeasy Mini Kit (Qiagen, Valencia, CA, USA). The cDNAs were amplified and quantified (PrimeScript RT reagent Kit, TaKaRa Bio, Kusatsu, Japan). The relative expression levels of mRNA were determined using a Roche Diagnostics LightCycler 2.0 Real-Time PCR System (Roche, Mannheim, Germany). The sequences of the real-time PCR primer pairs are shown in [Table 1](#pone.0218471.t001){ref-type="table"}. To ensure equal loading and amplification, all products were normalized to a β-actin transcript as an internal control.
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###### Sequence for forward and reverse primer sets used for real-time PCR.

![](pone.0218471.t001){#pone.0218471.t001g}

  Amplification   Forward primer                     Reverse primer
  --------------- ---------------------------------- --------------------------------
  LOX             `5’-CGACCCTTACAACCCCTACA-3’`       `5’-AAGTAGCCAGTGCCGTATCC-3’`
  α-SMA           `5′ -GACAATGGCTCTGGGCTCTGTAA-3′`   `5′ -CTGTGCTTCGTCACCCACGTA-3′`
  collagen1A      `5′ -GGAATGAAGGGACACAGAGG-3′`      `5′ -TAGCACCATCATTTCCACGA-3′`
  CTGF            `5′ -CTCCTGCAGGCTAGAGAAGC-3′`      `5′ -GATGCACTTTTTGCCCTTCTT-3′`
  fibronectin     `5′ -CTGGCCGAAAATACATTGTAA-3′`     `5′ -CCACAGTCGGGTCAGGAG-3′`
  RhoA            `5’ -CGTTAGTCCACGGTCTGGTC-3’`      `5’-GCCATTGCTCAGGCAACGAA-3’`
  PDGF-B          `5’ -TGATCTCCAACGCCTGCT-3’`        `5’-TCATGTTCAGGTCCAACTCG-3’`
  MCP-1           `5’ -CTGAAGCTCGTACTCTC-3’`         `5’-CTTGGGTTGTGGAGTGAG-3’`
  β-actin         `5′ -GTCCACCTTCCAGCAGATGT-3′`      `5′ -AAAGCCATGCCAATCTCATC-3′`

LOX: lysyl oxidase; α -SMA: smooth muscle actin; CTGF: connective tissue growth factor; TGF: transforming growth factor; PDGF: platelet derived growth factor; MCP: Monocyte chemoattractant protein.

Immunofluorescence staining {#sec014}
---------------------------

Confluent cells seeded on 6-well plates were infected with CMV AD169 at the indicated MOIs of 1 or 0.1 and fixed at 1 dpi, then the immediate-early (IE) antigens at 1 dpi were analyzed by immunofluorescence imaging as described previously \[[@pone.0218471.ref016]\]. After cells were fixed, treated, and incubated with a blocking buffer, the cells were immunolabeled with anti-CMV IE antibody (1:50) overnight at 4°C and stained with a secondary goat anti-mouse antibody for 1 h. Rhodamine phalloidin (Invitrogen) was used to visualize stress fiber structures. Images were obtained using inverted fluorescence microscopy (IX83; Olympus, Tokyo, Japan).

Statistical analysis {#sec015}
--------------------

For comparisons between two groups, the independent *t*-test was used. For comparison of results among three groups, one-way analysis of variance was performed. Experiments were performed in triplicate and representative results are reported. A value of *P* \< 0.05 was considered to indicate statistical significance.

Results {#sec016}
=======

The effects of dexamethasone, losartan, and ganciclovir on CMV viral replication {#sec017}
--------------------------------------------------------------------------------

After CMV infection in TM cells, the IE antigen was detected at 1 dpi, at high and low MOI ([Fig 1](#pone.0218471.g001){ref-type="fig"}) (also at 3 and 5 dpi, data in [S1](#pone.0218471.s001){ref-type="supplementary-material"} and [S2](#pone.0218471.s002){ref-type="supplementary-material"} Figs). The amount of viral DNA also increased at 1, 3, 5, and 7 dpi in human TM cells after CMV AD169 infection (solid line, [Fig 2A](#pone.0218471.g002){ref-type="fig"}). Dexamethasone treatment did not have significant effect on the CMV copy numbers at 1, 5, and 7 dpi, except at 3 dpi (*P* \< 0.05). Losartan treatment significantly decreased CMV copy number only at 7 dpi (*P* \< 0.05, [Fig 2B](#pone.0218471.g002){ref-type="fig"}). As expected, ganciclovir treatment significantly decreased the viral copy number at 3, 5, and 7 dpi (*P* \< 0.05; [Fig 2C](#pone.0218471.g002){ref-type="fig"}).

![Primary cultured human trabecular meshwork cell (TM) inoculated with human cytomegalovirus strain AD169.\
**Normal uninfected TM cells and TM cells at a multiplicity of infection of 0.1 or 1.** To confirm the infectivity of CMV AD 169, the infected cells were immunolabeled with an anti-IE1 antibody at 1 day post infection (dpi). IE, immediate early (green signal), and stress fibers with a Rhodamine Phalloidin (red signals). Bar = 200 μm.](pone.0218471.g001){#pone.0218471.g001}

![**Viral DNA accumulation after human cytomegalovirus infection and dexamethasone (A) losartan (B), and ganciclovir treatment (C) in human trabecular meshwork (TM) cells.** Cells were infected with CMV AD169 at a high multiplicity of infection (MOI; 1). Cells were harvested at 1, 3, 5, and 7 day after infection (dpi) and viral DNA was extracted from cells and processed for qPCR analysis of viral DNA accumulation (UL26). Real-time PCR with β -actin primers was performed to serve as an internal control for input DNA. Data are the averages of three independent DNA samples from the infected cells. Values are mean ± standard error.](pone.0218471.g002){#pone.0218471.g002}

The effects of dexamethasone, losartan, and ganciclovir on viability of TM cells {#sec018}
--------------------------------------------------------------------------------

The effects of dexamethasone, losartan, and ganciclovir on viability of TM cells were evaluated with MTS assay. Human TM cells were treated with various concentrations of dexamethasone (0, 100 μM) or losartan (0, 0.1 μM, 1 μM, 10 μM), or ganciclovir (0 μM, 10 μM, 100 μM) for 1, 3, 5, 7 days respectively. Cell viability of TM cells was not changed by any of the examined concentrations of agents across the experiments ([Fig 3](#pone.0218471.g003){ref-type="fig"}).

![**Effects of dexamethasone (A) losartan (B), and ganciclovir treatment (C) on viabilities of cultured TM cells.** Viabilities of TM cells evaluated using MTS assay were not changed by any concentration of treatment. Each value is expressed the mean ± SE.](pone.0218471.g003){#pone.0218471.g003}

CMV-induced secretion of TGF-β1 quantitated by ELISA {#sec019}
----------------------------------------------------

To identify the effect of CMV infection in outflow pathway, the expression of TGF- β1 were measured. When the CMV-induced secretion of TGF-β1 was examined by ELISA, significant increases in the concentration of TGF-β1 in the CMV-infected TM cells at MOI of 1 were detected at MOI of 3, 5, and 7 dpi (*P* \< 0.001; [Fig 4A](#pone.0218471.g004){ref-type="fig"}). Treatment with dexamethasone significantly decreased the secretion of TGF-β1 at 1, 3, 5, and 7 dpi ([Fig 4B](#pone.0218471.g004){ref-type="fig"}). Treatment with losartan (1 and 10 μM) also significantly decreased the levels of TGF-β1 at 1, 3, 5, and 7 dpi ([Fig 4C](#pone.0218471.g004){ref-type="fig"}). However, treatment with 10 μM ganciclovir did not affect the TGF-β1 levels throughout the observation period. There was a significant increase in TGF-β1 levels with 100 μM ganciclovir treatment ([Fig 4D](#pone.0218471.g004){ref-type="fig"}).

![**TGF-β1 production after human cytomegalovirus infection (A) and dexamethasone (B) losartan (C), and ganciclovir treatment (D) in human trabecular meshwork (TM) cells.**. Cells were infected with CMV AD169 at a high multiplicity of infection (MOI; 1). Cells were harvested at 1, 3, 5, and 7 days after infection (dpi). Supernatants were assayed for total TGF-β1 production using a TGF-β1 responsive luciferase bioassay. (A) Expression of TGF-β1 was increased 1 dpi (\**P* \< 0.05 vs. TGF-β expression 1 dpi; ^†^*P* \< 0.05 vs. TGF-β expression of the Mock infection). (B) Treatment with DEX significantly decreased the production of TGF-β1 5 dpi (\**P* \< 0.05 for TGF-β1 expression of CMV infection without DEX, CMV infection with DEX, and DEX treatment alone). Results are expressed as the mean ± standard deviation of three different experiments. DEX, dexamethasone.](pone.0218471.g004){#pone.0218471.g004}

Effect of losartan on TM cell fibrogenic activity {#sec020}
-------------------------------------------------

Based on above described observation on the role of CMV infection in TGF-β1 induction, we tested the effects of losartan on the expression profile of fibrogenic markers induced by TGF- β1 in human TM cells. Serum-starved TM cells treated with TGF-β1 along with the presence of losartan (0.1 μM, 1 μM, 10 μM) for 48 hours showed marked decrease in the expression of α-smooth muscle actin (SMA), lysyl oxidase (LOX), connective tissue growth factor (CTGF), fibronectin and collagen-1A, compared with TGF-β1 alone ([Fig 5](#pone.0218471.g005){ref-type="fig"}). Especially, the losartan treatment significantly decreased the expression of LOX and fibronectin in a dose-dependent manner ([Fig 5B and 5D](#pone.0218471.g005){ref-type="fig"}).

![Quantitative determination of mRNA expression levels according to losartan treatment with or without TGF- β1 for 48 hours.\
(A) expression of α-smooth muscle actin (SMA), (B) lysyl oxidase (LOX), (C) connective tissue growth factor (CTGF), (D) fibronectin, (E) RhoA, (F) collagen-1A, (G) PDGF-B, and (H) MCP-1 (\**P* \< 0.05 vs. transcripts from the unstimulated Mock infection).](pone.0218471.g005){#pone.0218471.g005}

Expression of fibrogenic and inflammatory molecules according to CMV infection with or without treatment with TGF-β1 and/or losartan using real-time PCR {#sec021}
--------------------------------------------------------------------------------------------------------------------------------------------------------

To ascertain the effect of losartan on CMV-infected TM cells, CMV-infected TM cells were stimulated with or without TGF-β1 and/or losartan to investigate their effects on the transcripts of potential fibrogenic molecules. Compared with unstimulated mock infection, CMV-infected TM cells stimulated by TGF-β1 showed significantly enhanced expression of α-SMA, LOX, CTGF, and fibronectin, which were decreased with additional treatment with 1 μM losartan ([Fig 6A--6D](#pone.0218471.g006){ref-type="fig"}).

![Quantitative determination of mRNA expression levels according to CMV AD169 infection with or without TGF- β1 and/or losartan (0.1 μM) 48 hours post infection.\
(A) expression of α-smooth muscle actin (SMA), (B) lysyl oxidase (LOX), (C) connective tissue growth factor (CTGF), (D) fibronectin, (E) RhoA, (F) collagen-1A, (G) PDGF-B, and (H) MCP-1 ((\**P* \< 0.05 vs. transcripts from the unstimulated Mock infection).](pone.0218471.g006){#pone.0218471.g006}

Compared with unstimulated mock infection, expression of RhoA and platelet-derived growth factor (PDGF)-B were significantly decreased after CMV infection. However, expression of monocyte chemoattractant protein (MCP)-1 significantly increased over 60-fold after CMV infection, and additional TGF-β1 treatment of CMV-infected TM cells decreased the expression of MCP-1 ([Fig 6E--6H](#pone.0218471.g006){ref-type="fig"}).

Discussion {#sec022}
==========

CMV is an important cause of retinitis in patients who have impaired T cell function, as a result of transplantation, AIDS, or immunosuppressive treatment. However, in the last 10 years, the involvement of CMV has been increasingly recognized in hypertensive anterior uveitis in immunocompetent, in which CMV DNA is detected in aqueous by PCR amplification \[[@pone.0218471.ref001]\]. The clinical features of CMV-induced anterior uveitis include Posner-Schlossmann syndrome, chronic anterior uveitis, and corneal endotheliitis. Especially, younger patients in their third to fifth decades with CMV anterior uveitis usually present with Posner-Schlossmann syndrome, which is characterized by minimal inflammation in anterior chamber, with minimal or no circumciliary injection, a single or a few central keratic precipitates \[[@pone.0218471.ref027]\].

TGF-β1 is known to be induced by CMV infection in various cells, mediating pro-fibrotic changes after CMV infection \[[@pone.0218471.ref013]--[@pone.0218471.ref015]\]. This study also confirmed that the secretion of TGF-β1 was significantly increased from 3 to 7 dpi in infected cells compared with mock-infected cells ([Fig 4A](#pone.0218471.g004){ref-type="fig"}), and the IE protein was found from 1 dpi ([Fig 1](#pone.0218471.g001){ref-type="fig"}) in human TM cells. These results were consistent with the previous finding that the TGF-β1 promoter is activated by the IE protein, and that enhanced TGF-β1 secretion is an early response to CMV infection \[[@pone.0218471.ref014]\].

Systemic RAS has an obligatory role in the regulation of blood pressure homeostasis, systemic fluid volume, and electrolyte balance. The circulatory RAS system is activated by renin, which cleaves angiotensinogen to form angiotensin I (Ang-I), which is then converted to angiotensin II (Ang-II) by the angiotensin-converting enzyme \[[@pone.0218471.ref028]\]. Ang-II regulates fibrosis, inflammation, and proliferation as well as vasoconstriction and electrolyte homeostasis through the activation of AT1R. The inhibition of Ang-II is effective in the prevention of cardiac remodeling and fibrotic conditions in renal and liver tissues \[[@pone.0218471.ref029]\]. Local RAS has been found in various extra-renal tissues, including the thymus, adrenal glands, and ocular tissues \[[@pone.0218471.ref022]\], and all recognized RAS components have been detected in human ocular tissue \[[@pone.0218471.ref020], [@pone.0218471.ref030]\]. The inhibition of Ang-II therefore represents a potential therapeutic target of ECM remodeling in ocular tissue.

The pro-fibrotic cascade by Ang-II is thought to be mediated by increased TGF-β, as reported by Kagami, et al. \[[@pone.0218471.ref023]\], and Ang-II treatment of rat mesangial cells in culture increased the levels of TGF-β. With the induction of TGF-β, Ang-II treatment of rat mesangial cells also enhanced the expression of matrix components biglycan, fibronectin, and collagen type 1, which was prevented by a competitive inhibitor of Ang-II \[[@pone.0218471.ref023]\]. Miguel-Carrasco et al. \[[@pone.0218471.ref031]\] showed that losartan metabolites showed anti-fibrotic effect by blockade of CTGF-induced LOX in fibroblast. Consistent with these results, in this study, losartan attenuated the expression of various fibrogenic molecules induced by TGF-β1, especially of LOX and fibronectin in a dose-dependent manner ([Fig 5B and 5D](#pone.0218471.g005){ref-type="fig"}). In this study, replication of viral DNA was reduced with losartan treatment at 7 dpi, as well as treatment with the anti-viral agent ganciclovir ([Fig 2B and 2C](#pone.0218471.g002){ref-type="fig"}). No additional cytotoxicity was noted with the treatment of dexamethasone, losartan, and ganciclovir ([Fig 3](#pone.0218471.g003){ref-type="fig"}). However, no dose-dependent response was noted with the application of losartan. In this regard, losartan appears to have a direct anti-fibrotic effect on human TM cells rather than working through the etiology of fibrosis of TM cells.

Interestingly, our study showed that the enhanced expression of TGF-β1 induced by CMV infection was significantly decreased by treatment with 1 μM losartan, which is a selective AT1R inhibitor ([Fig 4C](#pone.0218471.g004){ref-type="fig"}). Notably, we found that the expression of fibrogenic molecules such as α-SMA and CTGF was significantly elevated during CMV infection when stimulated by TGF-β1, which is present in the aqueous humor and functions in the normal physiology of the eye. The enhanced expression of fibrotic molecules (α-SMA, CTGF, LOX and fibronectin) was significantly reduced by treatment with losartan ([Fig 6](#pone.0218471.g006){ref-type="fig"}). TGF-β1 is one of the downstream molecules of Ang-II \[[@pone.0218471.ref019]\]. Therefore, inhibition of Ang-II would interrupt TGF-β1 following a pro-fibrogenic cascade during CMV infection in TM cells. Therefore, treatment with losartan may have therapeutic potential in the treatment of CMV anterior uveitis.

There is a possibility that the virus uses the RAS system in its infection. Virus-induced cardiac myopathy was decreased in the AT1R knockout mouse, suggesting that the AT1R signal is obligatory for the development of virus-induced myocardial injury \[[@pone.0218471.ref032]\]. It has also been reported that CMV infection stimulates the expression of renin and Ang-II in both kidney cells and the ECM in a dose-dependent manner \[[@pone.0218471.ref033]\]. The anti-viral properties of losartan have been reported by Gardner et al. \[[@pone.0218471.ref034]\], who showed that treatment with losartan caused a dose-dependent decrease in HSV-2 infectivity in cultured cardiac and Vero cells, suggesting that losartan prevents viral release from the cells. Further studies are needed to investigate potential anti-viral effect of losartan in CMV infection.

Our study also showed that CMV induced a 60-fold increase in the expression of MCP-1, which was decreased with TGF-β1 co-treatment ([Fig 6H](#pone.0218471.g006){ref-type="fig"}), whereas no significant changes in PDGF-B were noted ([Fig 6G](#pone.0218471.g006){ref-type="fig"}). It is known that CMV infection causes increased expression of several proinflammatory cytokines such as interleukin-6, tumor necrosis factor-α, and MCP-1 in serum in a CMV-infected animal model \[[@pone.0218471.ref033]\]. Importantly, MCP-1, which exhibits potent chemotactic activity in monocytes, is upregulated at an early stage of CMV infection \[[@pone.0218471.ref035]\]. In pancreatic cancer cells, Ang-II stimulates the expression of MCP-1 \[[@pone.0218471.ref036]\]. In a hyperuricemic nephropathy rat model, treatment with losartan decreased the expression of MCP-1 \[[@pone.0218471.ref037]\]. However, in our study, MCP-1 expression was not significantly affected by treatment with losartan. TGF-β1 is known to inhibit inflammation-medicated induction of MCP-1 in macrophages \[[@pone.0218471.ref038]\]. It is possible that stimulation with TGF-β1 greatly inhibited the expression of MCP-1, masking the effect of losartan on the expression of MCP-1. Further studies are therefore required to determine the effects of MCP-1 on the IOP regulatory mechanisms in CMV anterior uveitis.

Although there are many studies regarding the potential usage of RAS inhibitor as an ocular treatment, the clinical use of RAS inhibitor needs further studies on efficacy, pharmacokinetics, and safety. The application of systemic administration of losartan can impair the blood supply in the optic nerve head, potentially causing ischemic damage to retinal nerve fibers \[[@pone.0218471.ref020]\]. Considering that RAS components have also been identified in central structure of the eye, the local administration of RAS inhibitors including topical administration or intravitreal injection would be preferable.

Our study has limitations to be acknowledged. We used the laboratory strain AD169 throughout the experiment. Although AD169 is one of most widely used CMV strains, this is high passage laboratory strain, which has lost several virulence genes. The experiment was based on an *in vitro* infection model of cultured TM cells, rather than *in vivo* infection, which limits the clinical implication of the study. Further studies using animal model of CMV induced hypertensive uveitis are required.

In summary, CMV infection in human TM cells induced TGF-β1 as well as the pro-fibrotic cascade. The fibrotic changes induced by CMV infection were attenuated by treatment with losartan. Based on its effects on the modulation of fibrosis in TM cells, losartan may provide an effective treatment for patients with CMV-induced hypertensive anterior uveitis.
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###### Primary cultured human trabecular meshwork cell (TM) inoculated with human cytomegalovirus strain AD169 at 3 day post infection (dpi).

**Normal uninfected TM cells and TM cells at a multiplicity of infection of 0.1 or 1.** To confirm the infectivity of CMV AD 169, the infected cells were immunolabeled with an anti-IE1 antibody. IE, immediate early (green signal), and stress fibers with a Rhodamine Phalloidin (red signals). Bar = 200 μm.

(TIF)

###### 

Click here for additional data file.

###### Primary cultured human trabecular meshwork cell (TM) inoculated with human cytomegalovirus strain AD169 at 5 day post infection.

**Normal uninfected TM cells and CMV-infected TM cells at a multiplicity of infection of 0.1 or 1.** To confirm the infectivity of CMV AD 169, the infected cells were immunolabeled with an anti-IE1 antibody. IE, immediate early (green signal), and stress fibers with a Rhodamine Phalloidin (red signals). Bar = 200 μm.

(TIF)

###### 

Click here for additional data file.
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